Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label ibandronate loading dose study in lung cancer patients with painful bone metastases
2007-000885-20Phase 2Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibandronate in non-small cell lung cancer (NSCLC) and bone metastases, sponsored by Maastricht University Medical Center+. Primary endpoints: Bone pain response (primary) and Mean worst pain score on Brief Pain Inventory (BPI). Started May 2007; status: terminated.
02
Drugs
ibandronate
03
Conditions
non-small cell lung cancer (NSCLC)bone metastases
Beyond the preview
Go deeper on 2007-000885-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000885-20.